



Pharmacy Policy

Policy: Hepatitis COE

Line of Business: Non-Medicare

Effective Date: August 17, 2016

Revision Date: August 17, 2016

This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics Subcommittee.

Background:

The Hepatitis Center of Excellence (COE) Program was created due to the release of new oral Hepatitis C treatments. Evaluation of treatment options for Hepatitis C is complex. Current American Association for the Study of Liver Diseases (AASLD) guideline and DHCS provide treatment guidelines for the management of Hepatitis C. Clinicians should be aware of the monitoring parameters and treatment regimens endorsed by the state and AASLD. In addition, treatment-resistant Hepatitis B cases are increasing and must be evaluated appropriately. The COE is directed by experienced transplant hepatologists with at least 2+ years of experience with the new oral therapies.

Policy:

- This policy applies to all IEHP Medi-Cal Members
- All Hepatitis B & C referrals or treatment requests shall be directed to the COE. All prescriptions / treatment must be evaluated by the transplant hepatologist at the COE.
- Prescriptions shall be provided in conjunction with the Hepatitis B & C Program. A Pharmacy designated by the COE shall provide all Hepatitis B & C treatment according to the prescription order.
- Procedures:
 - All referrals and Pharmacy Exception Requests for Hepatitis B & C must be redirected to the COE.
 - The Pharmacy or Utilization Management (UM) department will make arrangements for Members to see the transplant hepatologist at the COE. Members will be monitored at the COE if treatment is initiated.
 - All prescriptions must be initiated by the experts at the COE and fulfilled by the designated pharmacy at the COE for monitoring purpose.